Pulmonary alveolar proteinosis

Sandeep M. Patel, Hiroshi Sekiguchi, Jordan P. Reynolds, Michael Joseph Krowka

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalCanadian Respiratory Journal
Volume19
Issue number4
StatePublished - Jul 2012

Fingerprint

Pulmonary Alveolar Proteinosis
Respiratory Physiological Phenomena
Macrophage Colony-Stimulating Factor
Antibodies
Bronchoalveolar Lavage
Standard of Care
Granulocyte-Macrophage Colony-Stimulating Factor
Dyspnea
Gases
Physicians
Population
Therapeutics

Keywords

  • Alveolar infiltrates
  • Crazy paving
  • GM-CSF
  • Pulmonary alveolar proteinosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Patel, S. M., Sekiguchi, H., Reynolds, J. P., & Krowka, M. J. (2012). Pulmonary alveolar proteinosis. Canadian Respiratory Journal, 19(4), 243-245.

Pulmonary alveolar proteinosis. / Patel, Sandeep M.; Sekiguchi, Hiroshi; Reynolds, Jordan P.; Krowka, Michael Joseph.

In: Canadian Respiratory Journal, Vol. 19, No. 4, 07.2012, p. 243-245.

Research output: Contribution to journalArticle

Patel, SM, Sekiguchi, H, Reynolds, JP & Krowka, MJ 2012, 'Pulmonary alveolar proteinosis', Canadian Respiratory Journal, vol. 19, no. 4, pp. 243-245.
Patel SM, Sekiguchi H, Reynolds JP, Krowka MJ. Pulmonary alveolar proteinosis. Canadian Respiratory Journal. 2012 Jul;19(4):243-245.
Patel, Sandeep M. ; Sekiguchi, Hiroshi ; Reynolds, Jordan P. ; Krowka, Michael Joseph. / Pulmonary alveolar proteinosis. In: Canadian Respiratory Journal. 2012 ; Vol. 19, No. 4. pp. 243-245.
@article{61eb228fdefc4c01a5893c57290129c5,
title = "Pulmonary alveolar proteinosis",
abstract = "Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.",
keywords = "Alveolar infiltrates, Crazy paving, GM-CSF, Pulmonary alveolar proteinosis",
author = "Patel, {Sandeep M.} and Hiroshi Sekiguchi and Reynolds, {Jordan P.} and Krowka, {Michael Joseph}",
year = "2012",
month = "7",
language = "English (US)",
volume = "19",
pages = "243--245",
journal = "Canadian Respiratory Journal",
issn = "1198-2241",
publisher = "Pulsus Group Inc.",
number = "4",

}

TY - JOUR

T1 - Pulmonary alveolar proteinosis

AU - Patel, Sandeep M.

AU - Sekiguchi, Hiroshi

AU - Reynolds, Jordan P.

AU - Krowka, Michael Joseph

PY - 2012/7

Y1 - 2012/7

N2 - Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.

AB - Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.

KW - Alveolar infiltrates

KW - Crazy paving

KW - GM-CSF

KW - Pulmonary alveolar proteinosis

UR - http://www.scopus.com/inward/record.url?scp=84865158634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865158634&partnerID=8YFLogxK

M3 - Article

C2 - 22891182

AN - SCOPUS:84865158634

VL - 19

SP - 243

EP - 245

JO - Canadian Respiratory Journal

JF - Canadian Respiratory Journal

SN - 1198-2241

IS - 4

ER -